癌症诊疗一体化研究进展  

Recent progress in cancer theranostics

作　　者：黄凯 林静 黄鹏 韩纲 陈小元[3] HUANG Kai;LIN Jing;HUANG Peng;Han Gang;CHEN Xiaoyuan(Department of Molecular Imaging,School of Biomedical Engineering,Health Science Center,Shenzhen University,Shenzhen 518060,China;Department of Biochemistry and Molecular Pharmacology,University of Massachusetts Medical School,Worcester,Massachusetts 01605,USA;National Institute of Biomedical Imaging and Bioengineering,National Institutes of Health,Bethesda,Maryland 20892,USA)

机构地区：[1]深圳大学医学部生物医学工程学院分子影像系,深圳518060 [2]美国马萨诸塞大学医学院生物化学与分子药理学系,美国伍斯特,马萨诸塞州01605 [3]美国国立卫生研究院生物医学影像及医学工程所,美国贝塞斯达,马里兰州20892

出　　处：《科技导报》2018年第22期12-26,共15页Science & Technology Review

摘　　要：癌症诊疗一体化是集癌症诊断和治疗于一体的新技术。通过将具有肿瘤诊断和治疗功能的组分同时整合到一个纳米平台上,获得纳米诊疗剂,有望实现肿瘤的早期诊断、精确定位、原位治疗,以及实现在治疗过程中的实时疗效监测与预后。本文概述了癌症诊疗一体化的发展历程,分析了诊疗一体化在癌症诊断和治疗过程中的独特优势,介绍了具有代表性的纳米诊疗剂,展望了癌症诊疗一体化领域未来的发展方向。Theranostics is a type of emerging biomedical technology that integrates diagnostics with therapeutics,thus possesses significant biomedical impact on various diseases,especially cancer,in terms of fundamental research and clinical applications.A cancer theranostic agent is usually composed of a diagnostic component,which allows for cancer imaging and detection,and a therapeutic component,which allows for cancer therapy.Through the integration of diagnosis and therapy in a single nanoparticle,several novel merits are expected, including accurate localization of tumor area,in situ therapy,and real-time monitoring of therapeutic progress.In this paper,we firstly introduce the development of cancer theranostics and analyze their unique advantages for cancer diagnosis and treatment.We then focuse on the latest progress on the construction of various cancer theranostic agents.In the end,we discusse the challenges and possible future directions of cancer theranostics.

关 键 词：癌症 诊疗一体化 诊断剂 诊疗剂 纳米医学 

分 类 号：R730[医药卫生—肿瘤]